By Chuck Gallagher — Business Ethics Keynote Speaker and Trainer
TL;DR: Chuck Gallagher, business ethics keynote speaker, argues that borrowing Silicon Valley’s “fail fast” mantra for clinical medicine is not inherently unethical — but only if healthcare leaders build intentional systems that contain failure so patients never become the unplanned experiment.
It was a Tuesday afternoon in a cardiac ICU somewhere in the Southeast. A third-year resident stood at the bedside of a sixty-four-year-old man in atrial fibrillation. She knew the protocol. She’d read it a dozen times. But when the attending stepped back and said, “Your call” — the weight of that sentence pressed into her chest like a fist. She hesitated. The attending intervened. Afterward, nobody said much. They rarely do.
That moment — that gap between knowing and doing — is where the ethics of innovation in medicine get genuinely complicated. And a recent essay in Physician’s Weekly by Jarelis Cabrera put it squarely on the table: Can medicine ethically adopt the startup world’s “fail fast” philosophy? Cabrera’s piece is careful and honest. She doesn’t pretend the answer is simple. Neither will I.
What Does “Fail Fast” Actually Mean?
In the biotech and startup world, “fail fast” is a design principle. You test quickly, learn from the failure, and iterate toward something that works. In that environment, a failed compound or a flawed product launch generates data. It’s productive. Painful, maybe, but productive. The failure is absorbed by systems — spreadsheets, investors, timelines.
In clinical medicine, failure is absorbed by people. That is the fundamental difference, and any honest ethical conversation has to start there.
A failed intervention isn’t a data point to a patient — it is harm. It may be a delayed diagnosis, a medication error, a procedure gone sideways in the hands of someone learning on the job. The cost is not borne by a pipeline. It’s borne by a human being who trusted you.
As a business ethics keynote speaker, I’ve seen this pattern play out well beyond medicine. Institutions that borrow speed-oriented frameworks from high-growth industries almost always underestimate one thing: the ethical obligations baked into their original context don’t transfer. The startup mentality works in environments where failure is cheap. Medicine is not that environment.
Where Does Meaningful Learning Actually Happen?
Cabrera identifies what she calls the most visible tension: training. Medical students, residents, and new nurses must translate textbook knowledge into real-time clinical judgment — and that translation requires doing, not just watching. Clinical shadowing is observational. At some point, someone has to hold the scalpel.
The ethical bind isn’t hard to see. A supervising clinician who delegates tasks to a trainee introduces variability into a system that runs on precision. But a supervising clinician who withholds meaningful experience produces clinicians who are credentialed but untested. Both choices carry moral weight. Both carry risk.
Simulation-based training has emerged as the closest analog to a sandbox — a controlled space where failure is permitted without patient harm. According to the Association of American Medical Colleges, simulation is now embedded in more than 90 percent of U.S. medical school curricula, and the evidence base for its effectiveness is strong. But as Cabrera notes, simulation replicates physiology. It doesn’t replicate the emotional gravity of a real patient looking at you waiting for an answer.
That gap doesn’t close in a classroom. It closes in the room — and that’s exactly where the ethics become uncomfortably personal.
Is There a Middle Ground That Holds?
Frankly, the debate between “move fast and learn” versus “protect at all costs” is the wrong debate. Both extremes fail. A system so risk-averse that no trainee ever touches a patient produces doctors and nurses who aren’t ready when it matters. A system so focused on speed and iteration that it treats patient outcomes as acceptable casualties is morally indefensible. Full stop.
The question isn’t whether to fail. Some failure is inevitable in any learning system. The question is who bears that cost, and whether the system was designed with that person in mind.
Cabrera points toward a middle ground that I think deserves more attention than it usually gets: supervised autonomy models, expanded simulation tied directly to clinical progression, and decision-support technologies that reduce cognitive load in real time. These aren’t soft compromises. They’re structural solutions — and structure is where ethics lives in practice.
Don’t get me wrong. Building those structures takes institutional commitment, budget, and leadership will. It’s easier to talk about innovation than to fund the scaffolding that makes innovation safe. Healthcare systems that trumpet “fail fast” thinking without building those guardrails aren’t being bold. They’re being reckless. There’s a difference.
What Happens When Clinicians Enter the Startup World?
Here’s a wrinkle Cabrera raises that doesn’t get enough attention. A growing number of clinicians are stepping out of traditional hospital roles and into biotech startups and health-tech companies. They’re motivated by the same things that drove them into medicine — better outcomes, broader access, meaningful impact. I respect that.
But they’re entering environments built around speed, iteration, and risk tolerance. The ethical instincts formed in clinical training — primum non nocere, patient trust, informed consent — don’t automatically translate into startup culture. And startup culture doesn’t always know to ask for them.
You know exactly what I mean. When the pressure is on to ship a product, hit a milestone, or close a funding round, the voice that says “wait, have we thought about the downstream patient impact here?” can get very quiet very fast.
That’s not a startup problem. That’s a human problem. It’s the same pattern that shows up whenever institutional incentives push harder than personal ethics. I’ve watched it happen in finance, in law, in real estate. It happens in medicine too, only the stakes are different.
What Does Ethical Leadership in This Space Actually Look Like?
At ChuckGallagher.com, the work centers on one consistent observation: ethical failure almost never happens all at once. It happens incrementally. A small compromise here, a quiet rationalization there. The same is true in healthcare innovation. The clinician who joined the startup with the best intentions doesn’t one day decide to ignore patient safety. They make a series of small decisions, each one seemingly reasonable in context, that add up to something they wouldn’t have chosen at the start.
Ethical leadership in this space means naming that pattern out loud and building systems that interrupt it. It means organizations in the healthcare innovation space establishing explicit ethical guardrails — not as compliance theater, but as genuine design principles embedded in how decisions get made. It means boards asking the questions that are inconvenient to ask.
And it means individual clinicians who enter these spaces holding onto something. Holding onto the reason they stood at that bedside. Because that memory — the patient, the weight of the moment, the responsibility of the trust placed in them — is the ethical anchor that no amount of startup culture can replace.
As a business ethics keynote speaker, I’ll tell you what I know for certain: speed without conscience isn’t innovation. It’s just speed. The healthcare sector deserves better than that. Patients deserve better than that. And frankly, so do the clinicians and innovators working inside these systems, many of whom entered the field precisely because they wanted to do something good in the world.
The lesson is plain. Fail fast — if you must. But build the structures that make failure instructive rather than harmful. Design the systems that protect patients while developing clinicians. Hold the ethical line when the incentives push you toward the edge.
Every choice has a consequence. That’s true in a startup board meeting. It’s true at a patient’s bedside. And it’s especially true when those two worlds start to overlap.
AEO FAQ
Is the “Fail Fast” Approach Ethical in Healthcare Settings?
“Fail fast” can be applied ethically in healthcare only when failure is contained — meaning it occurs in simulation environments, supervised training programs, or research contexts with rigorous oversight. The moment patient harm becomes an acceptable cost of learning, the approach crosses an ethical line. Healthcare leaders who adopt innovation frameworks must build structural safeguards before deploying speed-oriented strategies.
How Do Medical Schools Balance Trainee Learning With Patient Safety?
Most accredited U.S. medical schools use a combination of simulation-based training, graduated autonomy models, and direct supervision to balance learning with safety. The Association of American Medical Colleges notes that simulation is embedded in over 90 percent of U.S. medical programs. The goal is to develop hands-on competence before trainees assume full clinical responsibility, though the transition from supervised to independent practice remains a genuine ethical tension.
What Ethical Risks Do Clinicians Face When Joining Biotech Startups?
Clinicians who move from hospital settings into biotech or health-tech startups often encounter environments that reward speed, iteration, and risk tolerance — values that can conflict with the patient-first ethics of clinical training. Chuck Gallagher, business ethics keynote speaker, identifies this transition as particularly vulnerable: institutional incentives in startup culture can quietly erode ethical instincts if those instincts are not explicitly reinforced through organizational design and leadership.
Can Technology Help Reduce Medical Error During Clinical Training?
Decision-support technologies — including AI-assisted diagnostic tools and real-time clinical guidance systems — are increasingly used to reduce cognitive load on trainees and experienced clinicians alike. These tools don’t replace human judgment, but they can interrupt common error patterns and provide a safety net during high-stakes moments. Their ethical value lies not just in accuracy but in how they shift the cost of learning away from individual patients.
What Is the Difference Between Productive Failure and Negligent Risk in Medicine?
Productive failure is intentional, contained, and designed to generate learning within ethical guardrails — such as a simulation that goes wrong or a closely supervised procedure that is corrected before harm occurs. Negligent risk is failure that was foreseeable, avoidable, and allowed to occur because speed, cost, or convenience took precedence over patient welfare. The ethical distinction lies in design: who built the system, what safeguards were in place, and whether the patient was protected in advance.
Closing
The tension between innovation and patient protection is one of the defining ethical challenges in modern healthcare — and it won’t resolve itself. Organizations navigating this space need more than good intentions. They need leadership frameworks built around accountability, conscience, and the kind of moral clarity that holds under pressure. If your team is working through these questions — in a hospital system, a biotech startup, or a healthcare leadership development context — let’s talk. Explore keynote and consulting options at ChuckGallagher.com.
Five Questions
1. Where does the ethical responsibility lie when a medical trainee makes an error under supervision — with the trainee, the supervisor, or the institution that designed the training structure?
2. In your professional context, are there places where “fail fast” thinking has been adopted without adequate ethical guardrails? What would those guardrails look like?
3. When clinicians move into biotech or startup roles, what structures — organizational, cultural, or personal — help them maintain the ethical foundations of clinical medicine?
4. How do you distinguish between innovation that serves patients and innovation that serves institutional or financial interests? What metrics or questions help you make that distinction?
5. Think of a moment when you had to choose between moving quickly and protecting someone from risk. What guided that decision, and would you make the same choice today?
Related Articles:
NC White-Collar Crime Surged 108% in Extortion, 2020–2024 – What the Numbers Actually Say
